The Levels of Amyloid -Protein and P181 in Peripheral Blood of Patients with Alzheimer's Disease Combined with Helicobacter pylori Infection and Their Clinical Significance.

OBJECTIVE

To analyze the levels of amyloid -protein and P181 in peripheral blood of patients with Alzheimer's disease combined with Helicobacter pylori infection and their clinical significance.

METHOD

From January 2019 to June 2020, 59 patients were enrolled in this experiment including the AD group with 27 patients and the normal control group with 32 patients. The patients were divided into two groups: Alzheimer's disease (AD) group ( = 27) and control group ( = 32), collecting the general data of patients, analyzing the diagnostic specificity and sensitivity of serum p-tau181 and A42 and their influence on prognosis, and comparing the serum A42 and p-tau181 concentrations for different HP infection degrees.

RESULT

Single diagnostic sensitivity of A42, p-tau181, and A42 combined p-tau181 was 0.863, 0.854, and 0.972, respectively, and their specificity was 0.048, 0.206, and 0.305, respectively. Compared with the single diagnosis of serum A42 and p-tau181, the combined diagnosis has higher sensitivity and specificity ( < 0.05); age, years of education, serum A42, and p-tau181 are factors affecting the prognosis of patients with Alzheimer's disease combined with Helicobacter pylori infection; the concentration of A42 in the control group was higher than that in the AD group, there was a statistical difference in the A42 concentration between the two groups ( < 0.05), and there was no statistical difference in the concentration of p-tau181 between the two groups ( > 0.05); the HP positive infection rate of the AD group and the control group was 63.0% and 35.7%, respectively. The HP negative infection rate of the AD group and the control group was 37.0% and 64.3%, respectively. Compared with the control group, the positive rate of HP in the AD group was higher, and the difference was statistically significant ( < 0.05); compared with HP-negative patients, HP-positive patients had a higher A42 concentration, and the difference was statistically significant ( < 0.05). The concentration of p-tau181 in the two groups was not statistically significant ( > 0.05); A42 gradually increases with increasing HP infection degree, and there are significant differences in serum A42 levels between different degrees of infection. However, the level of serum p-tau181 does not change significantly with the increase of infection.

CONCLUSION

There are significant alterations in the expression levels of A42 and p-tau181 in peripheral blood of AD patients, and the levels of A42 are related to HP infection; A42 and p-tau181 are potential biomarkers for AD diagnosis and treatment.